Short Interest in NLS Pharmaceutics Ltd. (NASDAQ:NCEL) Decreases By 27.7%

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) was the recipient of a large drop in short interest in January. As of January 30th, there was short interest totaling 88,032 shares, a drop of 27.7% from the January 15th total of 121,686 shares. Based on an average trading volume of 85,876 shares, the days-to-cover ratio is currently 1.0 days. Currently, 2.3% of the shares of the stock are short sold. Currently, 2.3% of the shares of the stock are short sold. Based on an average trading volume of 85,876 shares, the days-to-cover ratio is currently 1.0 days.

NLS Pharmaceutics Trading Down 0.7%

NLS Pharmaceutics stock traded down $0.02 during midday trading on Friday, reaching $2.77. 12,581 shares of the company were exchanged, compared to its average volume of 66,024. The firm’s 50-day simple moving average is $2.65 and its 200-day simple moving average is $11.04. NLS Pharmaceutics has a 1 year low of $1.89 and a 1 year high of $30.80.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded shares of NLS Pharmaceutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, NLS Pharmaceutics has a consensus rating of “Sell”.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.